Skip to content
Medical Health Aged Care

Canberra lightens the overload of Australia’s most common genetic disorder

Haemochromatosis Australia 2 mins read

MEDIA RELEASE 

The National Carillon and Old Canberra House are among 100 well-known buildings and landmarks across Australia will turn red from tonight until 7 June, shining a light on an extremely common genetic condition that most people have never heard of.

It is part of a worldwide initiative to raise awareness of haemochromatosis – also known as iron overload – and to prompt people to get tested. Most people know that having too little iron in your body can cause anaemia, which is characterised by tiredness and lethargy, but few people know that the same symptoms can also be caused by having too much iron.

The hereditary condition, which is passed on from both biological parents, is simple to detect and treat but if undiagnosed or ignored can lead to serious and life-threatening illness, including liver disease and diabetes. One in seven Australians carry one copy of the defective gene, while and one in 200 Australians have two copies, which puts them at high risk of developing the condition.

Dr Dan Johnstone, an iron researcher who also has the condition, says early detection is key to minimising or preventing permanent damage. “Awareness of haemochromatosis is more important now than ever as early diagnosis will help save lives, cut health costs and reduce unnecessary suffering for so many individuals and families. Everybody is different; some people will have early symptoms of fatigue or joint aches while others won’t know they have the condition until the damage is already done. Anyone who suspects they may have this condition should ask their GP for a blood test. Haemochromatosis is not a burden in your life if you get on to it early. Early diagnosis is key to managing and reducing complications. It is usually managed by a regime of therapeutic blood donations, at an Australian Red Cross Lifeblood donor centre. This is a classic win-win situation, benefiting both the individual and the community,” said Dr Johnstone.

Haemochromatosis Australia spokesperson, Tony Moorhead, said, “Despite being the most common genetic disorder in Australia, haemochromatosis is often underdiagnosed because people don’t know about it and symptoms are non-specific. Unfortunately, most of those affected aren’t diagnosed until aged in their mid-forties and already suffering ill health. “There are people with the condition who should have been diagnosed decades earlier. This would have reduced the suffering, medical cost and even loss of life that results from iron overload. If haemochromatosis is detected early enough it is completely preventable – those affected need never get sick, they simply need to donate blood to maintain normal iron levels and their health.” Mr Moorhead says. “Hereditary haemochromatosis is estimated to cost Australia’s health system about $280 million annually and to add further cost burdens by compounding other chronic conditions.” Haemochromatosis is easy to test, simple to treat but tragic to ignore. -

 

ENDS Landmarks lighting up can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/


Key Facts:

* Australia's most common genetic disorder, that most have never heard of

* World Haemochromatosis Awareness Week June 1 - 7 

*Interviews available

* Landmarks lighting up red can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/ 

* Interviews available


About us:

To find out more visit www.ha.org.au/haemochromatosis


Contact details:

Kellie Curtain M: 0412339690 [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 10/02/2026
  • 23:41
Helus Pharma

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this yearThis news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form…

  • Medical Health Aged Care
  • 10/02/2026
  • 19:26
Takeda Pharmaceutical Company Limited

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin…

  • Contains:
  • Medical Health Aged Care
  • 10/02/2026
  • 16:32
Dementia Australia

Release of Framework for National Dementia Action Plan welcome but further investment is urgently needed

Dementia Australia welcomes the release of the Collective Priority Framework for the National Dementia Action Plan, but says further investment is urgently needed to address the growing impact of dementia in Australia. The Commonwealth and all state and territory Health Ministers have agreed the urgent priorities for action are: Empowering individuals and communities to minimise risk where they can, and delay onset and progression. Improving dementia diagnosis and post-diagnostic care and support. Improve dementia data, maximise the impact of dementia research and promote innovation. Dementia Australia CEO Professor Tanya Buchanan said the release of the framework is a positive development…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.